Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Energy & metal in favour today
Thu, 7 Aug 01:30 pm

Indian share markets continued to trade on a weak note in the post-noon trading session. Barring energy and metal, all the sectoral indices are trading in the red with IT and pharma stocks being the biggest losers.

BSE-Sensex is down 96 points and NSE-Nifty is trading 22 points down. BSE Mid Cap is trading 0.5% down and BSE Small Cap index is trading up by 0.4%. The rupee is trading at 61.48 to the US dollar.

Majority of the cement stocks are trading in the red with J K Lakshmi Cement and Heidelberg Cement being the major losers whereas ACC and Ambuja Cement are among the few stocks trading in the green. As per a leading financial daily, Ultratech Cement is contemplating capital spends of Rs 37.9 bn in FY15. Under its capital expenditure plans, the company wants to add 2.9 million tonnes capacity with supporting grinding units and waste heat recovery in its subsidiary Aditya Cement Works in Rajasthan. Additionally, the company will also invest in modernizing its facility at its jetty in Gujarat. The company has earmarked capital investments of Rs 30.5 bn in FY16 and Rs 2 bn in FY17. Ultratech expects its installed capacity to rise from the present 62 million tonnes to 70 million tonnes by early next year. As per the company, its turnover is expected to reach Rs 250 bn in FY15 from Rs 200.7 bn registered in FY14. Ultratech Cement's stock is currently trading up by 1%.

Majority of the domestic pharma stocks are trading negative with J B Chemicals and Indoco Remedies posting maximum losses. As per a leading financial daily, Cadila Healthcare's listed subsidiary Zydus Cadila has received approval from US Food and Drug Administration (USFDA) to market potassium citrate extended-release tablets in the 5mEq, 10mEq and 15mEq strengths. These tablets are used in the prevention of kidney stones. As per IMS data, the estimated sales for potassium citrate ER tablets is $ 131.7 m. Cadila Healthcare presently has 94 approvals and has filed 239 abbreviated new drug applications so far. Cadila Healthcare's stock is trading up by 0.5%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Energy & metal in favour today". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.